Immunocore Holdings plc has grown revenue 32% a year over three years and 82% a year over five. Revenue growth, 3-year annual rate: +32% (Biotechnology median +17%). Revenue growth, 5-year rate: +82%, growth has slowed since the five-year average. Years of annual history on file: 5, FY2021 to FY2025, as filed.

IMCRImmunocore Holdings plc

Healthcare

$29.39-9.8% 1Y

$29.39

$27.7952 weeks$40.22

Is it growing?

Good

Operating margin widening (+20.9 points). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

Margin direction+20.9 points operatingSEC EDGAR · Jun 30, 2026

Trailing-twelve-month operating margin, -5.4% now against -26.2% a year earlier.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is IMCR growing?

Immunocore Holdings plc has grown revenue 32% a year over three years and 82% a year over five.

+32%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +82%
Revenue growth, 5-year rate · +32% over three · growth has slowed since the five-year average
Years of annual history on file: 5
Years of annual history on file · FY2021 to FY2025, as filed

Details›